Printer Friendly

Articles from M2 Pharma (November 9, 2016)

1-17 out of 17 article(s)
Title Author Type Words
Adaptimmune names Tal Zaks to board. 147
Amryt receives orphan drug designation for acromegaly compound AP102 from the US FDA. 145
Asterias Biotherapeutics doses first spinal cord injury patient with AST-OPC1 20m cells cohort in SCiStar clinical trial. 326
Bayer seeks approval for liver cancer drug Stivarga from US FDA. 142
BD unveils first diabetic syringe designed for use with Humulin R U-500 insulin. 283
CTI BioPharma incurs lower net loss of USD29.2m in Q3 2016. Financial report 168
Emergent BioSolutions appoints Kathryn C. Zoon, PhD to board. 207
First Patient Implanted in Trial of EndoStim's Lower Esophageal Sphincter Stimulation for GERD. 411
Flexion Therapeutics widens net loss to USD17.8m in Q3 2016. Financial report 153
GeoVax Labs collaborates with ViaMune. 133
Lexicon Pharmaceuticals receives research, development and commercialisation rights to LX9211. 209
Mallinckrodt receives US FDA approval for OFIRMEV IV bag presentation. 184
Mylan and Biocon files proposed biosimilar trastuzumab with US FDA. 241
North America Wearable Sensors Market to Reach USD 118.62m by 2018, Research and Markets Predicts. 288
pSivida hires Deb Jorn as EVP of corporate and commercial development. 152
Relevium Technologies appoints new Advisory Board members. 247
Sorrento Therapeutics reports purchase of majority of SCILEX. 232

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters